“Baricitinib Provides Sustained, Long-Term Efficacy With Consistent Safety for Up to 5 Years of Treatment in Adults With Severe Alopecia Areata: Final Results From BRAVE-AA1 and BRAVE-AA2”, J of Skin, vol. 9, no. 6, p. s662, Nov. 2025, doi: 10.25251/t6v95c18.